CASI Pharmaceuticals Files August 2025 Report
Ticker: CASIF · Form: 6-K · Filed: Aug 4, 2025 · CIK: 1962738
| Field | Detail |
|---|---|
| Company | Casi Pharmaceuticals, INC. (CASIF) |
| Form Type | 6-K |
| Filed Date | Aug 4, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: filing, press-release
Related Tickers: CASI
TL;DR
CASI Pharma dropped an August 6-K with a press release on 8/4.
AI Summary
CASI Pharmaceuticals, Inc. filed a Form 6-K on August 4, 2025, reporting information for the month of August 2025. The filing includes a press release dated August 4, 2025, as Exhibit 99.1. The company's principal executive office is located in Beijing, People's Republic of China.
Why It Matters
This filing provides an update on CASI Pharmaceuticals' activities and disclosures for August 2025, which is important for investors to stay informed about the company's ongoing operations and any material information released.
Risk Assessment
Risk Level: low — This is a routine filing (6-K) that primarily contains a press release and does not appear to disclose significant new financial or operational risks.
Key Players & Entities
- CASI Pharmaceuticals, Inc. (company) — Filer of the report
- August 4, 2025 (date) — Date of the press release and filing
- Beijing, People's Republic of China (location) — Location of principal executive office
FAQ
What type of report is CASI Pharmaceuticals filing?
CASI Pharmaceuticals, Inc. is filing a Form 6-K, which is a Report of Foreign Private Issuer.
What is the filing date of this Form 6-K?
The Form 6-K was filed as of August 4, 2025.
What is included as an exhibit in this filing?
Exhibit 99.1 is a Press Release of CASI Pharmaceuticals, Inc. dated August 4, 2025.
Where are CASI Pharmaceuticals' principal executive offices located?
The principal executive offices are located at 1701-1702, China Central Office Tower 1, No. 81 Jianguo Road, Chaoyang District, Beijing, 100025, People's Republic of China.
Does CASI Pharmaceuticals file annual reports under Form 20-F or 40-F?
The registrant indicates it files annual reports under cover of Form 20-F.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on August 4, 2025 regarding CASI Pharmaceuticals, Inc. (CASIF).